Earnings Call · Q4 FY2023·2024-02-29

Q4 23EPS +16.28%·Rev n/aQ3 23EPS +51.19%·Rev n/aQ2 23EPS +91.04%·Rev n/aQ1 23EPS +100.00%*·Rev n/a⚠ consensus missing

ANI PHARMACEUTICALS INC ANIP

Judy DiClemente — Investor Relations

Nikhil Lalwani — President and Chief Executive Officer

Stephen Carey — Chief Financial Officer

+12.3%1d on move date+11.9% vs SPY3d+10.2%5d+9.2%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ANIP calls or request research access.

More ANIP calls Browse calls Request research access